HC Wainwright & Co. Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $9

Benzinga Newsdesk www.benzinga.com Neutral 55.6%

Neg 0% Neu 55.6% Pos 0%

HC Wainwright & Co. analyst Sara Nik initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $9.